Pyrrolopyridine derivative preparation method

Inventors

Kim, Kyungjin • KIM, Uk-Il • BANG, Hyung Tae

Assignees

ST Pharm Co Ltd

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12612400-B2

Patent

Publication Date

2026-04-28

Expiration Date


Abstract

The present invention relates to a method for preparing a pyrrolopyridine derivative compound exhibiting antiviral activity, and a novel intermediate used therein. The preparation method of the present invention enables reaction steps to be reduced through effective process development and a high purity pyrrolopyridine derivative compound to be prepared in a high yield, and thus enables production costs to be remarkably reduced so as to be economical and to be suitable for mass production.

Core Innovation

The invention provides a method for preparing a compound represented by Chemical Formula I through a sequential, multi-step transformation of defined intermediate chemical formula compounds. The method addresses the inefficient, multi-step prior-art synthesis of an antiviral pyrrolopyridine derivative represented by Chemical Formula I and streamlines the synthesis by using defined intermediate structures, Chemical Formulas 3 to 6, and a defined sequence of steps S-1 to S-5.

The method includes cyclization steps that convert a compound represented by Chemical Formula 1 or a salt thereof together with a butanone derivative represented by Chemical Formula 2 into Chemical Formula 3, followed by cyclization with an acetopyruvate derivative to prepare Chemical Formula 4. The method then prepares Chemical Formula 5 from Chemical Formula 4 by a chiral reduction, prepares Chemical Formula 6 from Chemical Formula 5 by an alkylation, and prepares Chemical Formula I from Chemical Formula 6 by a hydrolysis.

The description also includes examples and reaction schemes supporting that the intermediate-to-intermediate transformations can be carried out to reach Chemical Formula I. The chiral reduction is described as forming stereochemically enriched intermediates, and structures for intermediates labeled III/IV/V/V-I/VI are shown with analytical characterization such as NMR and LCMS reported.

Claims Coverage

The independent claim covers a five-step method to prepare Chemical Formula I, structured around five inventive features: cyclization to Chemical Formula 3, cyclization to Chemical Formula 4, chiral reduction to Chemical Formula 5, alkylation to Chemical Formula 6, and hydrolysis to Chemical Formula I. Additional scope includes definitions of X as Cl, Br, or I and R as C1-4 alkyl.

Five-step intermediate-based preparation of Chemical Formula I

A method for preparing a compound represented by Chemical Formula I comprising: S-1, preparing Chemical Formula 3 by cyclization of Chemical Formula 1 or a salt thereof and a butanone derivative represented by Chemical Formula 2; S-2, preparing Chemical Formula 4 by cyclization of Chemical Formula 3 and an acetopyruvate derivative; S-3, preparing Chemical Formula 5 from Chemical Formula 4 by a chiral reduction; S-4, preparing Chemical Formula 6 from Chemical Formula 5 by an alkylation; and S-5, preparing Chemical Formula I from Chemical Formula 6 by a hydrolysis.

Halogen and alkyl substituent definitions for the route

The method where X is Cl, Br or I, and R is C1-4 alkyl.

Overall, the claim set centers on a sequential S-1 to S-5 route that proceeds through intermediates Chemical Formulas 3 to 6 using cyclization, chiral reduction, alkylation, and hydrolysis, with substituent scope defined by X and R. Dependent claim refinements further specify the hydrolysis mode, the salt form, and particular named reagents and conditions for the chiral reduction and alkylation.

Stated Advantages

The disclosed approach streamlines the synthesis.

Produces stereochemically enriched intermediates and products, with reported ee values for at least one intermediate.

Documented Applications

Preparation of an antiviral pyrrolopyridine derivative represented by Chemical Formula I.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.